Summary
Edwards Lifesciences Corporation (EW) has filed an 8-K report on February 11, 2025, to announce its fourth quarter 2024 financial results. The primary purpose of this filing is to provide investors with the official release of the company's performance metrics for the period ending December 31, 2024. This report serves as the primary source for detailed financial outcomes, including revenue, profitability, and other key operational indicators that shape the company's current financial standing. Investors should pay close attention to the press release, furnished as Exhibit 99.1, which contains the comprehensive financial details for the fourth quarter of 2024. While this 8-K filing itself does not contain the detailed financial statements, it directs stakeholders to the official press release for these critical figures. The information provided in this release will be instrumental in assessing the company's recent performance and its implications for future financial health and strategic direction.
Key Highlights
- 1Edwards Lifesciences (EW) filed an 8-K on February 11, 2025.
- 2The filing announces the company's financial results for the fourth quarter of 2024.
- 3The press release containing the Q4 2024 financial results is furnished as Exhibit 99.1.
- 4This exhibit is incorporated by reference into the 8-K filing.
- 5The report directs investors to the press release for detailed financial performance data.
- 6The information furnished under Item 2.02 is not considered 'filed' for SEC purposes.